Status:
RECRUITING
A Study With CIT-013 in HS Patients
Lead Sponsor:
Citryll BV
Conditions:
Hidradenitis Suppurativa (HS)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Doe...
Eligibility Criteria
Inclusion
- Male or female participants with HS of more than 6 months duration,
- 18 years of age at screening visit,
- Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or III (according to Hurley classification system),
- A total abscess and inflammatory nodule (AN) count of ≥ 5 at screening and Day 1 prior to enrollment/randomization,
- Participant must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a contraindication to oral antibiotics for treatment of their HS,
- Total draining tunnel count less than 20
Exclusion
- Any current and/or recurrent clinically significant skin condition in the treatment area other than HS,
- Prior treatment with a recombinant therapeutic protein during the 6 weeks before baseline
- Prior treatment with any of the following medications before baseline:
- Any other systemic therapy for HS (28 days before baseline)
- Any IV anti-infective therapy (14 days before baseline)
- History of malignancy with exception of non-melanoma skin cancer that has been excised and cured,
Key Trial Info
Start Date :
October 31 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT06993233
Start Date
October 31 2025
End Date
July 1 2027
Last Update
November 20 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus UMC
Rotterdam, Netherlands
2
GB-05
Chester, United Kingdom